We are thrilled to announce that the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has officially approved Haystack MRD® for use in identifying residual or recurring disease in patients with solid tumor cancers.
This approval broadens patient access, as circulating tumor DNA (ctDNA) testing with Haystack MRD is now authorized in all 50 US states.
Read more here about how achieving one of the nation’s highest clinical laboratory standards underscores the quality and technical rigor of Haystack MRD.
